You just read:

Medimetriks Pharmaceuticals Focuses on Advancing MM36 (difamilast) Through Phase 3 Trials; Extinguishes Debt Owed to Knight Therapeutics

News provided by

Medimetriks Pharmaceuticals, Inc.

Jun 18, 2019, 17:00 ET